Yeoh Eric E, Holloway Richard H, Fraser Robert J, Botten Rochelle J, Di Matteo Addolorata C, Butters Julie, Weerasinghe Sujeeva, Abeysinghe Prasad
Department of Radiation Oncology, Royal Adelaide Hospital, Adelaide, Australia.
Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1072-83. doi: 10.1016/j.ijrobp.2006.06.005. Epub 2006 Sep 11.
The aim of this study was to compare the toxicity and efficacy of radiation therapy (RT) for localized carcinoma of the prostate, using a hypofractionated (55 Gy/20 fractions/4 weeks) vs. a conventionally fractionated (64 Gy/32 fractions/6.5 weeks) dose schedule.
A total of 217 patients were randomized to either the hypofractionated (108 patients) or the conventional (109 patients) dose schedule, with planning with two-dimensional (2D) CT scan planning methodology in the majority of cases. All patients were followed for a median of 48 (6-108) months. Gastrointestinal (GI) and genitourinary (GU) toxicity was evaluated before RT and after its completion using modified late effects of normal tissue-subjective, objective, management, analytic (LENT-SOMA) scales and the European Organization for Research and Treatment of Cancer sexual function questionnaire. Efficacy of RT based on clinical, radiologic, and prostate-specific antigen data were also evaluated at baseline and after RT.
Gastrointestinal and GU toxicity persisted 5 years after RT and did not differ between the two dose schedules other than in regard to urgency of defecation. However, 1-month GI toxicity was not only worse in patients with the hypofractionated RT schedule but also adversely affected daily activities. Nadir prostate-specific antigen values occurred at a median of 18.0 (3.0-54.0) months after RT. A total of 76 biochemical relapses, with or without clinical relapses, have occurred since; of these, 37 were in the hypofractionated and 39 in the conventional schedule. The 5-year biochemical +/- clinical relapse-free and overall survival was 55.9% and 85.3% respectively for all patients, and did not differ between the two schedules.
Radiation therapy for prostate carcinoma causes persistent GI toxicity that is largely independent of the two dose schedules. The hypofractionated schedule is equivalent in efficacy to the conventional schedule.
本研究旨在比较大分割放疗(55 Gy/20次/4周)与常规分割放疗(64 Gy/32次/6.5周)剂量方案用于局限性前列腺癌放射治疗的毒性和疗效。
总共217例患者被随机分为大分割放疗组(108例患者)或常规放疗组(109例患者),大多数病例采用二维(2D)CT扫描计划方法进行计划制定。所有患者的中位随访时间为48(6 - 108)个月。在放疗前和放疗完成后,使用改良的正常组织晚期效应主观、客观、管理、分析(LENT - SOMA)量表和欧洲癌症研究与治疗组织性功能问卷对胃肠道(GI)和泌尿生殖系统(GU)毒性进行评估。还在基线和放疗后根据临床、放射学和前列腺特异性抗原数据评估放疗疗效。
放疗后5年胃肠道和GU毒性持续存在,除排便急迫性外,两种剂量方案之间无差异。然而,大分割放疗方案患者的1个月胃肠道毒性不仅更严重,而且对日常活动产生不利影响。放疗后前列腺特异性抗原最低值出现在中位时间18.0(3.0 - 54.0)个月。自那以后,共发生了76例生化复发,有无临床复发均算在内;其中,大分割放疗组37例,常规放疗组39例。所有患者的5年生化±临床无复发生存率和总生存率分别为55.9%和85.3%,两种方案之间无差异。
前列腺癌放射治疗会导致持续的胃肠道毒性,这在很大程度上与两种剂量方案无关。大分割放疗方案在疗效上与常规放疗方案相当。